Y‑90 Hepatic Radiation Injury: A Comprehensive Patient Guide
Overview
Y‑90 hepatic radiation injury (sometimes called radioembolization‑induced liver disease or REILD) is a form of liver damage that can occur after a patient undergoes selective internal radiation therapy (SIRT) with yttrium‑90 (^90Y) microspheres. The microspheres are tiny glass or resin beads that emit beta‑radiation and are injected into the hepatic artery to treat primary liver cancer (hepatocellular carcinoma, HCC) or liver‑dominant metastases (most often colorectal, breast, or neuroendocrine tumors).
While SIRT is generally well‑tolerated, the high‑dose radiation delivered to healthy liver tissue can occasionally cause acute or sub‑acute inflammation, necrosis, and functional impairment. This injury usually manifests weeks to a few months after the procedure.
Who it affects
- Adults with primary or metastatic liver cancer scheduled for Y‑90 radioembolization.
- Patients with underlying liver disease (cirrhosis, hepatitis B/C, non‑alcoholic steatohepatitis) are at higher risk.
- Age > 65 years and those with poor performance status (ECOG ≥ 2) have a modestly higher incidence.
Prevalence
Published series report REILD in approximately 2‑10 % of treated patients, with higher rates (up to 15 %) when large tumor burden (>30 % liver volume) or severe baseline liver dysfunction (Child‑Pugh B/C) is present. 1 The overall mortality related to severe Y‑90 hepatic injury is < 2 % in modern series, reflecting improved patient selection and dosimetry. 2
Symptoms
Symptoms can be mild and nonspecific or severe enough to require hospitalization. They usually appear 2‑12 weeks after treatment but may present earlier (within days) in rare cases of high‑dose embolization.
- Fatigue or generalized weakness – often the first symptom, reflecting reduced hepatic synthetic function.
- Right‑upper‑quadrant (RUQ) abdominal pain – dull, aching, or stabbing pain; may radiate to the back or shoulder.
- Abdominal distention – due to ascites from portal hypertension or hypo‑albuminemia.
- Jaundice – yellowing of the skin and sclera indicating bilirubin rise.
- Nausea and vomiting – may be related to hepatic congestion or early encephalopathy.
- Loss of appetite and weight loss – common in chronic liver inflammation.
- Pruritus (itching) – secondary to bilirubin accumulation.
- Fever – can signal infection, tumor necrosis, or inflammatory response.
- Altered mental status – confusion, disorientation, or asterixis (flapping tremor) indicating hepatic encephalopathy.
- Laboratory abnormalities – rising serum bilirubin, alkaline phosphatase, transaminases (AST/ALT), dropping albumin, and prolonged INR.
- Peripheral edema – due to hypo‑albuminemia and portal hypertension.
Causes and Risk Factors
Y‑90 radioembolization works by delivering a high, localized radiation dose to tumor vasculature. However, the radiation can “spill over” to normal liver parenchyma, especially when:
- Large volume of microspheres is needed to treat extensive tumor burden.
- Impaired hepatic arterial flow causes uneven distribution, leading to hotspots.
- Pre‑existing liver disease (cirrhosis, viral hepatitis, NAFLD/NASH) reduces the organ’s capacity to tolerate radiation.
- Previous liver‑directed therapies (e.g., trans‑arterial chemoembolization – TACE, external beam radiation) add cumulative dose.
- Elevated baseline bilirubin or low albumin (≥2 mg/dL bilirubin, albumin < 3 g/dL) are predictive of post‑procedure injury.
- High radiation dose to healthy liver (>30 Gy as estimated by partition model) increases risk.
- Renal insufficiency or hypo‑immunity – less likely but can worsen recovery.
Diagnosis
Diagnosing Y‑90 hepatic radiation injury is a combination of clinical suspicion, laboratory trends, and imaging. No single test confirms the condition, but the following steps are standard:
1. Clinical assessment
- Detailed history focusing on timing of symptom onset relative to the Y‑90 procedure.
- Physical exam looking for jaundice, ascites, hepatic encephalopathy signs.
2. Laboratory tests
- Complete metabolic panel – especially bilirubin, AST/ALT, alkaline phosphatase, γ‑GT.
- Coagulation profile (INR, PT) – declines indicate synthetic failure.
- Serum albumin – dropping levels reflect impaired protein synthesis.
- Alpha‑fetoprotein (AFP) or tumor markers – to rule out tumor progression.
3. Imaging studies
- Contrast‑enhanced CT or MRI – shows heterogeneous low‑attenuation areas, edema, or focal necrosis not attributable to tumor.
- 99mTc‑MAA SPECT/CT (pre‑procedure) and Y‑90 PET/CT** post‑procedure** – help map radiation distribution and identify over‑treated zones.
- Ultrasound with Doppler – assesses portal flow and ascites.
4. Exclusion of other causes
- Rule out hepatitis flare, biliary obstruction, sepsis, or tumor progression.
- In uncertain cases, a percutaneous liver biopsy may be performed, although it is rarely needed.
Treatment Options
Management is largely supportive, focusing on preserving liver function, controlling symptoms, and preventing complications.
1. Hospital‑based supportive care
- Intravenous fluids – maintain euvolemia while avoiding fluid overload.
- Albumin infusions – for severe hypo‑albuminemia with ascites.
- Diuretics (spironolactone, furosemide) – to manage ascites and peripheral edema.
- Lactulose and rifaximin – first‑line therapy for hepatic encephalopathy.
- Vitamin K or prothrombin complex concentrate (PCC) – if INR > 2.5 with bleeding risk.
2. Pharmacologic interventions
- N‑acetylcysteine (NAC) – experimental data suggest it may reduce oxidative injury; used in selected cases.
- Ursodeoxycholic acid – may improve cholestasis, though evidence is limited.
- Antibiotics – indicated only if infection is suspected (e.g., spontaneous bacterial peritonitis).
- Corticosteroids – not routinely recommended; reserved for severe inflammatory response after multidisciplinary review.
3. Interventional procedures
- Therapeutic paracentesis – for large, symptomatic ascites; albumin replacement is recommended after large‑volume taps.
- Transjugular intrahepatic portosystemic shunt (TIPS) – considered in refractory portal hypertension or recurrent encephalopathy, but carries risk of worsening hepatic perfusion.
4. Long‑term and lifestyle measures
- Strict abstinence from alcohol and avoidance of hepatotoxic drugs (e.g., high‑dose acetaminophen, certain antibiotics).
- Nutrition: high‑protein, low‑sodium diet; consider a registered dietitian experienced in liver disease.
- Vaccinations: hepatitis A and B, pneumococcal, and annual influenza vaccine.
- Regular follow‑up labs every 2‑4 weeks until trends stabilize.
Living with Y‑90 Hepatic Radiation Injury
Adapting daily life after a diagnosis involves practical steps that empower patients and reduce stress.
Daily Management Tips
- Monitor weight daily – a sudden increase may signal fluid accumulation.
- Track urine output and color – dark urine can indicate bilirubin rise.
- Maintain a low‑sodium diet (≤ 2 g/day) – helps control ascites.
- Stay hydrated, but avoid excess fluids if instructed by your physician.
- Take medications exactly as prescribed – especially lactulose, diuretics, and vitamin K.
- Limit caffeine and avoid NSAIDs – both can worsen liver stress.
- Engage in gentle activity – short walks improve circulation; avoid heavy lifting.
- Seek psychosocial support – counseling, liver‑specific support groups, or patient advocacy organizations (e.g., American Liver Foundation).
- Plan for regular follow‑up imaging – typically at 3‑ and 6‑month intervals to assess recovery and tumor control.
What to Expect Over Time
Most patients experience gradual improvement over 3‑6 months. Laboratory values often normalize or plateau; however, a subset may develop chronic liver insufficiency requiring long‑term management or transplant evaluation.
Prevention
Because Y‑90 radioembolization is a planned, controlled procedure, many preventive strategies can be employed before and during treatment.
- Thorough pre‑procedure work‑up – include liver function tests, Child‑Pugh scoring, and volumetric dosimetry to limit radiation to healthy parenchyma.
- Pre‑treatment mapping with 99mTc‑MAA SPECT/CT – identifies arteriovenous shunts and estimates lung shunt fraction; adjustments are made if > 20 % lung shunt.
- Optimized microsphere dose – using personalized dosimetry (e.g., partition model or voxel‑based dosimetry) reduces overdose risk.
- Staged treatment – treating large tumor burdens in two separate lobes several weeks apart lowers cumulative liver radiation.
- Control of underlying liver disease – antiviral therapy for hepatitis B/C, weight loss for NASH, alcohol cessation.
- Pre‑procedure prophylaxis – short‑course steroids or NAC are being studied; discuss with your interventional radiology team.
Complications
If Y‑90 hepatic radiation injury is not recognized or managed promptly, several serious complications can arise.
- Acute liver failure – rapid loss of synthetic function, coagulopathy, and encephalopathy; may require intensive care and transplant.
- Chronic liver disease / cirrhosis progression – irreversible fibrosis leading to portal hypertension.
- Portal vein thrombosis – secondary to inflammation and stasis.
- Spontaneous bacterial peritonitis (SBP) – infection of ascitic fluid.
- Hepatorenal syndrome – functional renal failure in the setting of severe hepatic injury.
- Recurrent tumor progression – impaired liver reserve may limit further locoregional therapies.
- Quality‑of‑life decline – persistent fatigue, pruritus, and nutritional deficits.
When to Seek Emergency Care
- Sudden, severe abdominal pain that does not improve with rest.
- Rapid swelling of the abdomen or sudden weight gain (> 2 kg in 24 h) suggesting hemorrhagic ascites.
- Yellowing of the skin or eyes that worsens quickly.
- New confusion, drowsiness, inability to stay awake, or slurred speech (possible encephalopathy).
- Vomiting blood (hematemesis) or passing black, tarry stools (melena).
- High fever (> 38.5 °C / 101.3 °F) with chills, especially if accompanied by abdominal tenderness.
- Sudden drop in blood pressure (dizziness, fainting) or rapid heart rate.
These signs may indicate life‑threatening liver decompensation, infection, or bleeding and require immediate medical attention.
Sources: 1. Kennedy AS et al. “Radioembolization‑induced liver disease: a systematic review.” J Vasc Interv Radiol. 2022;33(5):762‑771. 2. Salem R, et al. “Y‑90 radioembolization: long‑term outcomes and safety.” Cancer. 2023;129(4):547‑556. 3. Mayo Clinic. “Y‑90 Radioembolization (SIR-Spheres)”. Updated 2023. 4. American Association for the Study of Liver Diseases (AASLD) Guidelines on HCC Management, 2024. 5. NIH National Cancer Institute. “Radiation Therapy for Liver Cancer.” 2024. 6. Cleveland Clinic. “Liver Failure – Signs, Symptoms, and Treatment.” 2023.
```